TOP TEN perturbations for 39587_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39587_at
Selected probe(set): 206016_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39587_at (206016_at) across 6674 perturbations tested by GENEVESTIGATOR:
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):2.9773693Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):2.527381Number of Samples:2 / 8
| Experimental | male infertility study 1 (juvenile; Ad-) |
| Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells. | |
| Control | normal testicular lobules tissue (mJS10) |
| Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):2.4768276Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal B-cell sample |
| MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
male infertility study 1 (juvenile; Ad+) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):2.29992Number of Samples:5 / 8
| Experimental | male infertility study 1 (juvenile; Ad+) |
| Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained typical level of A-dark (Ad+) spermatogonial cells. | |
| Control | normal testicular lobules tissue (mJS10) |
| Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):2.1972313Number of Samples:20 / 19
| Experimental | atopic dermatitis study 12 (non-lesional; adults) |
| Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (non-lesional; children) |
| Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):-2.1870852Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)
Relative Expression (log2-ratio):2.1458187Number of Samples:20 / 18
| Experimental | atopic dermatitis study 12 (lesional; adults) |
| Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (lesional; children) |
| Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):1.9943771Number of Samples:2 / 2
| Experimental | conditioned medium study 1 (HS27a) |
| CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
| Control | untreated monocyte (CD14+) sample |
| Untreated CD14+ monocytes from two different donors. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):1.9777231Number of Samples:2 / 2
| Experimental | conditioned medium study 1 (HS5) |
| CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
| Control | untreated monocyte (CD14+) sample |
| Untreated CD14+ monocytes from two different donors. |
expO peritoneal cancer study 1 (serous surface papillary carcinoma; metastatic) / expO peritoneal cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Relative Expression (log2-ratio):1.8613281Number of Samples:2 / 12
| Experimental | expO peritoneal cancer study 1 (serous surface papillary carcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary serous surface papillary carcinoma of the peritoneum. | |
| Control | expO peritoneal cancer study 1 (papillary serous cystadenocarcinoma; metastatic) |
| Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the peritoneum. |